Heng Fai Ambrose Chan’s activist stake in DSS, Inc. fell to 86.3%, with beneficial ownership reported at 26,311,715 shares. The position matters to investors because the reported percentage is based on 10,042,518 shares outstanding as of September 8, while the ownership includes direct holdings, affiliated entities, convertible notes and warrants.

Key Highlights

  • Chan reported beneficial ownership of 26,311,715 shares, representing 86.3%.
  • The reported ownership percentage uses 10,042,518 DSS shares outstanding as of September 8, 2026.
  • Heng Fai Ambrose Chan beneficially owns 86.3% of DSS based on 26,311,715 shares and related securities.

DSS, Inc. (AMEX: DSS) reported that Heng Fai Ambrose Chan beneficially owns 86.3% of its common stock. His reported beneficial ownership covers 26,311,715 shares. The position is classified as activist under Schedule 13D. Chan’s ownership includes direct holdings, stock held through affiliated entities, convertible promissory notes and common stock purchase warrants. The ownership percentage is based on 10,042,518 DSS shares outstanding as of September 8, 2026.

Chan’s Beneficial Position

The 26,311,715-share position includes 1,002,978 shares held by Heng Fai Holdings Limited and 1,031,944 shares held directly by Chan. Alset Inc (NASDAQ: AEI). holds 2,581,268 DSS common shares and a $500,000 convertible Promissory Note initially convertible into 581,395 shares. The reported position therefore includes both common stock and securities that may convert into or provide rights to acquire DSS common stock.

September 3 Share Sale

Chan sold 21,852 DSS common shares on September 3, 2026, at $0.82 per share. The filing reports this transaction. The common stock carries a Par Value of $0.02 per share. The ownership update identifies September 3, 2026, as the transaction date.

September 8 Ownership Basis

The 86.3% calculation uses 10,042,518 DSS common shares outstanding as of September 8, 2026. The same outstanding-share figure is used for the stated beneficial ownership calculation under Rule 13d-3 of the Securities Exchange Act of 1934, as amended. Chan signed in his individual capacity and also signed for Alset Inc. Global Biomedical Pte. Ltd. and Alset International Limited. His listed roles include chief executive officer of Alset Inc. director of Global Biomedical Pte.